MarketPulse
E

$EXAS

2 articles found
2 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott Labs Stock Slides 22% on Weak Diagnostics, But Dividend Investors See Opportunity

$ABT down 22% after disappointing earnings, but strong medical devices and $21B Exact Sciences deal offer recovery potential for income seekers.
ABTEXAShealthcaredividend stock
The Motley FoolThe Motley Fool··James Halley

Abbott Laboratories Positions as Dividend Growth Play Amid Diagnostic Headwinds

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.
ABTEXASTLRYacquisitionhealthcare